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Most deaths in Western countries can currently be associated with fibrotic diseases. During 
fibrosis excessive amounts of extra-cellular matrix components, such as collagen, are 
deposited in tissues, which can lead to tissue stiffness and organ failure. The underlying 
mechanisms leading to tissue fibrosis remain poorly understand and, consequently, our 
capacities to treat fibrotic diseases remain limited. Currently approved drugs only delay the 
progression of fibrosis and are often associated with severe side-effects, which limit their 
clinical application. Thus, a better understanding of the ontology of fibrotic diseases and the 
development of more specific and more efficient drugs for the treatment of tissue fibrosis is 
an urgent clinical meet. 
 
Myofibroblasts are the major producers of extra-cellular matrix components and an 
expansion of myofibroblasts is observed during fibrosis. In mice, it is well established that 
blood vessel associated pericytes are the major source of myofibroblasts in fibrotic tissues 1. 
In particular, the local activation of the Transforming Growth Factor beta (TGFβ) induces the 
differentiation of pericytes into myofibroblasts during the development of tissue fibrosis 1. 
The Epidermal Growth Factor (EGF) like growth factor Amphiregulin has recently been 
identified as being a critical factor that induces this local activation of TGFβ on pericytes and 
thus their differentiation into myofibroblasts 2. Amphiregulin is a cytokine, involved in 
immunity against helminth infection, in immune regulation and in wound repair 3. In 
accordance with the finding that Amphiregulin is an important driver for myofibroblast 
differentiation under inflammatory conditions, it has also been shown in various different 
model systems that Amphiregulin deficient mice are resistant to the development of tissue 
fibrosis 4, while the injection of recombinant Amphiregulin into mice can induce fibrosis. 
However, these different mouse models are rather short-term models, while the ontology of 
human fibrotic diseases, based on chronic, local inflammation can stretch over several 
years. Furthermore, in human fibrotic diseases an Epithelial-Mesenchymal-Transition (EMT) 
seems to contribute to the expansion of myofibroblasts. Also EMT is a TGFβ-driven process; 
nonetheless, these differences between humans and mouse models raised the question 
whether the underlying mechanisms for the development of tissue fibrosis can be translated 
into a human setting. In particular, whether Amphiregulin is also a driver of tissue fibrosis in 
humans. 
 
In this regard, a recent publication by Todd et al. constitutes a major step forward 5. The 
authors studied chronic lung allograft dysfunction (CLAD), a chronic inflammatory disease in 
lung transplant patients, which is characterized by excessive matrix deposition, leading to 
loss of lung function. They followed two cohorts of lung-transplant patients, who either 
developed CLAD or not. They found that the expression of Amphiregulin in the lungs of 
patients with CLAD is significantly higher than in those without CLAD. Critically, the authors 
also followed individual patients in a longitudinal study and found that increases in 
Amphiregulin expression in the lungs of patients directly correlated with the development of 
CLAD. Given the findings in mouse models, these data derived from these patient cohorts 
strongly suggests that also in CLAD patients Amphiregulin is a major driver of tissue fibrosis. 
 
The finding that an EGF-like growth factor could contribute to tissue fibrosis may appear 
counter-intuitive at first, as a substantial fraction of cancer patients being treated with EGFR 
inhibitors develop lung fibrosis. But not only the low-affinity EGFR ligand Amphiregulin plays 
a critical role in the development of tissue fibrosis, but also the high-affinity ligand heparin-
binding EGF-like growth factor (HB-EGF). The EGFR shows a so-called “agonistic bias”, 
 3 
which means that ligands with different affinities induce the activation of different down-
stream signalling pathways (Figure 1). Consequently, the low affinity-ligand Amphiregulin 
induces the activation of TGFβ (Minutti), while the high-affinity ligand HB-EGF activates the 
intracellular inhibitor of TGFβ-signalling TIGIF; in this way, preventing the differentiation of 
pericytes into myofibroblasts 6. As a consequence, Hbegf-/- mice develop more severe forms 
of tissue fibrosis 6. The application of EGFR inhibitors in patients may thus block this HB-
EGF-mediated physiological counterbalance to TGFβ signalling and may thereby allow for 
the progression of an underlying form of tissue fibrosis in EGFR inhibitor treated cancer 
patients. 
 
Thus, taken together, the publication by Todd et al. 5 suggests a novel more refined 
approach for the treatment of tissue fibrosis, by targeting specifically Amphiregulin function. 
Furthermore, treating patients with lung transplants with such drugs could be an attractive 
first target group, as the development of CLAD is a rather frequent and predictable event, 
which could precisely be measured during clinical trials. Success of such drugs, such as for 
instance an Amphiregulin-neutralizing antibody, could then open the opportunity of applying 
such a drug to other fibrotic diseases and thus creating hope for resolving a major unmet 
clinical need. 
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Figure 1: The differential expression of two antagonistic EGF-like growth factors 
determines the functionality of local TGFβ. 
The low affinity EGFR ligand Amphiregulin induces a sustained activation of PLCγ signalling. 
Such signalling induces the “inside-out” activation of integrin-αv and thus the local, integrin-
mediated release of bio-active TGFβ. In contrast, the high-affinity EGFR ligand HB-EGF 
induces the activation of the MAPK signalling pathway. The pronounced ERK activation 
induces the accumulation of TGIF, an intracellular repressors of TGFβ signalling. (HB-EGF 
induced EGFR signalling is depicted in green, while Amphiregulin induced EGFR signalling 
is depicted in red. TGFβ signalling is depicted in blue.) 
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